Extending beyond HCC to other cancers, our results suggest that in the combination setting, a patient does not necessarily need to have an ASS1-deficient tumor to reap benefit from an ADI-PEG 20 and cisplatin drug treatment. Here, ASS1 is linked to hepatocellular carcinoma.